Waldenstrom's Macroglobulinemia Clinical Trials

60 clinical trials for Waldenstrom's Macroglobulinemia across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies — RECRUITING · PHASE1
• Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms — RECRUITING
• Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma — RECRUITING
• A MULTI-CENTER, OPEN-LABEL, SINGLE-ARM PHASE II TRIAL OF BENDAMUSTINE, RITUXIMAB AND THE SECOND GENERATION BTK INHIBITOR ACALABRUTINIB IN PREVIOUSLY UNTREATED WALDENSTROM¿S MACROGLOBULINEMIA (BRAWM) — RECRUITING · PHASE2
• Phase II multicenter study of immuno-chemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for symptomatic Waldenstrom's macroglobulinemia — COMPLETED · PHASE2
• A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia — ACTIVE_NOT_RECRUITING · PHASE4
• Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia - A MULTICENTER OPEN LABEL, SINGLE ARM EUROPEAN PHASE II STUDY (ECWM-2) — TERMINATED · PHASE2
• Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders — ACTIVE_NOT_RECRUITING
• Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia — TERMINATED · PHASE2
• Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia — ACTIVE_NOT_RECRUITING · PHASE2
• Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) — TERMINATED · PHASE2
• Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. — ACTIVE_NOT_RECRUITING
• Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia — NOT_YET_RECRUITING · NA
• Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) — COMPLETED · PHASE2
• A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) — COMPLETED · PHASE3
• A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 — COMPLETED · PHASE1
• Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia — COMPLETED · PHASE3
• A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia — TERMINATED · PHASE1
• R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia — OTHER · PHASE2
• A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia — OTHER · PHASE2
• AN OPEN-LABEL, MULTICENTER PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE BCL2 INHIBITOR SONROTOCLAX (BGB-11417) AS MONOTHERAPY AND IN COMBINATION WITH ZANUBRUTINIB (BGB-3111) IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA — COMPLETED · PHASE2
• Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing — COMPLETED · PHASE2
• Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies — TERMINATED · PHASE1
• Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia — COMPLETED · PHASE2
• Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia — TERMINATED · PHASE1
• Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia — COMPLETED · PHASE3
• LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia — COMPLETED · PHASE2
• Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's — COMPLETED · PHASE2
• Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) — COMPLETED · PHASE2
• A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma — COMPLETED · PHASE2
• Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia — COMPLETED · PHASE2
• Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia — COMPLETED · PHASE2
• Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies — COMPLETED · PHASE1
• Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia — TERMINATED · PHASE1
• Study of MLN8237 in Participants With Advanced Hematological Malignancies — COMPLETED · PHASE1
• Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients — COMPLETED · PHASE2
• Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia — COMPLETED · PHASE2
• Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia — COMPLETED · PHASE2
• Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors — COMPLETED · PHASE1
• A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia — COMPLETED · PHASE2
• Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 — COMPLETED · PHASE1
• Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia — COMPLETED · PHASE2
• Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia — OTHER · PHASE1
• Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies — COMPLETED · PHASE1
• Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia — TERMINATED · PHASE2
• Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia — TERMINATED · PHASE1
• CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia — TERMINATED · PHASE2
• Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia — COMPLETED · PHASE2
• Simvastatin in Waldenstrom's Macroglobulinemia — TERMINATED · PHASE2

Refine this search